Nodality, Inc., which is focused on solving drug development challenges,
announced today the availability of its new PathPro™ Chronic Lymphocytic
Leukemia (CLL) panels. These panels are designed to characterize cell
pathways associated with disease signaling at the single cell level and
to analyze the activity of therapeutics commonly used or in development
to treat CLL. Earlier this year, Nodality introduced its first PathPro
products, which leverage the unique capabilities of Nodality’s
proprietary multiparametric flow cytometry platform to study the
functional activity of customer therapeutics and identify disease
subgroups and differential activities in pathways or diseases. In
addition to the PathPro CLL panels, Nodality has launched the PathPro
JAK-STAT, PathPro TLR, and the PathPro AML panels. The Company
anticipates additional PathPro product launches in 2015.
Laura Brege, CEO and President of Nodality, Inc., stated, “We are
pleased with the reception of our PathPro products and are excited to
expand our offerings to drug developers. PathPro CLL panels allow
researchers the opportunity to study potency and specificity of newly
developed biologics, small molecule inhibitors, and chemotherapeutics
developed for use in the treatment of CLL.”
Nodality’s PathPro products are based on the Company’s broad knowledge
and experience in diverse signaling pathways and in interrogating
signaling at the single cell level in numerous cell types. For each
PathPro product, customers are able to select modulators, pathways, cell
types and donor sample types to be interrogated in targeted, small-scale
studies. The results provide critical insights into the functional
impact of drugs and drug candidates in disease sub-groups, identify
differential in vitro activities, pathway-specific profiles and/or
disease profiles, while addressing mechanism of action (MOA), efficacy
(IC50s) and comparison of compound activities.
-
PathPro™ CLL panels
Nodality’s PathPro Chronic Lymphocytic
Leukemia (CLL) panels enable analysis of multiple functional signaling
pathways across cell subsets, including CLL and normal B cells, T
cells, and monocytes. By applying this technology, an association
between B-cell receptor signaling and disease progression has been
demonstrated (Cesano,
et al., Haematologica (2013) 98, 626), and CLL B cells have
also been shown to respond to CD40 and Toll-Like Receptor modulation.
As with other PathPro and SCNP offerings, the PathPro CLL panels allow
for high-throughput, quantitative flow cytometry analysis of current
and investigational therapeutics as single agents or in combination.
For more information on the PathPro CLL panels, please visit: http://nodality.com/products-disease-offerings-cll.html.
In addition to the four PathPro products already launched, Nodality will
be introducing additional PathPro panels this year: PathPro TCR, PathPro
BCR, PathPro PD-1, PathPro IMR, and PathPro Th1/2/17 Polarization. The
new panels are designed to target additional drug development needs in
autoimmune diseases, hematological cancers and immuno-oncology.
About Single Cell Network Profiling
Nodality’s proprietary Single Cell Network Profiling (SCNP) technology,
a multiparametric flow cytometry-based platform, provides robust, human
cell-based translational models of disease, drug activity and patient
responses. SCNP reveals complex biology by characterizing cell signaling
networks in millions of cells at the single cell level. It creates
competitive advantages in addressing many of the most pressing
challenges in drug discovery and development. SCNP technology, coupled
with Nodality’s proprietary data analysis and visualization tools,
uniquely reveals complex functional biology to inform more effective
drug development decisions.
Originally developed at Stanford University, SCNP does not require
physical isolation of cell subsets and therefore provides real time
information on cell-cell interactions, identifies the functional
signaling capacity of rare cell subsets (such as drug-resistant cells
and stem cell populations) reveals the functional consequences of
epigenetic mutations and enables the interrogation of immune cell
communication and dysfunction in disease.
About Nodality
Nodality is a life science company whose technology platform, SCNP,
bridges the gap left by traditional R&D approaches. Nodality provides
clinically actionable solutions throughout the full discovery and
development process, including disease profiling, drug profiling,
clinical development, and life cycle management. Nodality’s team has
expertise in identifying solutions across a broad therapeutic landscape,
with a focus on immunology and oncology, including immuno-oncology.
Nodality has established multi-year strategic collaborations with UCB
Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson &
Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the
discovery and development of new therapeutic compounds. Major investors
include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp.
For more information on Nodality, please visit www.nodality.com.
Copyright Business Wire 2015